Targeted screening for high-risk groups: It is essential to design strategies that effectively target high-risk populations, such as individuals with a family history of ovarian cancer or known genetic predispositions, such as BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and ovarian carcinoma.